Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study Protocol for Multicentric Hospital-Based Diabetes Registry-Clinical Trial Network.

Indian journal of endocrinology and metabolism·2025
Same author

Clinical and Hormonal Profile of Classical 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia: Experience from a Tertiary Centre In India.

Indian journal of endocrinology and metabolism·2024
Same author

Digital Twin in Managing Hypertension Among People With Type 2 Diabetes: 1-Year Randomized Controlled Trial.

JACC. Advances·2024
Same author

Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.

PLoS medicine·2024
Same author

Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Cureus·2024
Same author

Bone Mineral Density and Bone Turnover Marker in a Subclinical Thyrotoxic State in Young Premenopausal Women.

Cureus·2024

Related Experiment Video

Updated: Feb 16, 2026

An Efficient and Reproducible Protocol for Distraction Osteogenesis in a Rat Model Leading to a Functional Regenerated Femur
09:26

An Efficient and Reproducible Protocol for Distraction Osteogenesis in a Rat Model Leading to a Functional Regenerated Femur

Published on: October 23, 2017

7.9K

Osteogenesis Imperfecta.

Justin Easow Sam1, Mala Dharmalingam1

  • 1Department of Endocrinology, Ramaiah Medical College, Bengaluru, Karnataka, India.

Indian Journal of Endocrinology and Metabolism
|December 30, 2017
PubMed
Summary
This summary is machine-generated.

Osteogenesis imperfecta, a heritable connective tissue disorder, is often caused by Type I collagen mutations. Treatment primarily involves bisphosphonate therapy, with variable patient outcomes.

Keywords:
Bisphosphonatecollagenosteogenesis imperfecta

More Related Videos

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects
07:35

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Published on: April 11, 2012

18.9K
A Mouse Distraction Osteogenesis Model
04:24

A Mouse Distraction Osteogenesis Model

Published on: November 14, 2018

6.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

An Efficient and Reproducible Protocol for Distraction Osteogenesis in a Rat Model Leading to a Functional Regenerated Femur
09:26

An Efficient and Reproducible Protocol for Distraction Osteogenesis in a Rat Model Leading to a Functional Regenerated Femur

Published on: October 23, 2017

7.9K
Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects
07:35

Creating Rigidly Stabilized Fractures for Assessing Intramembranous Ossification, Distraction Osteogenesis, or Healing of Critical Sized Defects

Published on: April 11, 2012

18.9K
A Mouse Distraction Osteogenesis Model
04:24

A Mouse Distraction Osteogenesis Model

Published on: November 14, 2018

6.8K

Area of Science:

  • Genetics
  • Biochemistry
  • Orthopedics

Background:

  • Osteogenesis imperfecta is a prevalent genetic disorder affecting connective tissues.
  • Mutations in Type I collagen genes account for approximately 90% of cases.
  • Classified into Types I-V (autosomal dominant) and VI-XIII (autosomal recessive), with severity graded 1-5.

Purpose of the Study:

  • To summarize the key aspects of Osteogenesis Imperfecta.
  • To outline diagnostic and therapeutic approaches.
  • To provide an overview of the condition's genetic basis and prognosis.

Main Methods:

  • Genomic testing, including collagen analysis from fibroblasts, is utilized for diagnosis.
  • Classification based on inheritance patterns (autosomal dominant/recessive) and severity grading.
  • Review of current treatment strategies.

Main Results:

  • Type I collagen mutations are the predominant genetic cause.
  • A grading system (1-5) reflects disease severity.
  • Bisphosphonate therapy is the established primary treatment.

Conclusions:

  • Osteogenesis imperfecta is a genetically diverse disorder primarily linked to collagen defects.
  • Accurate diagnosis through genomic testing guides treatment decisions.
  • Bisphosphonate therapy offers a primary treatment modality, though prognosis remains variable.